We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Novel MRI Method Could Predict Early Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

By MedImaging International staff writers
Posted on 18 Sep 2023
Print article
Image: A new MRI exam could predict chemotherapy’s effectiveness in breast cancer patients (Photo courtesy of 123RF)
Image: A new MRI exam could predict chemotherapy’s effectiveness in breast cancer patients (Photo courtesy of 123RF)

Neoadjuvant chemotherapy is often administered to shrink tumors before surgery in patients with breast cancer. However, due to the varying mutations within the same genes in breast tumors, almost 80% of patients experience either partial or no response to traditional chemotherapy. The conventional way to evaluate a patient's reaction to chemotherapy is by monitoring changes in the size of the tumor, a process that can take between four and six months and multiple treatment cycles. Researchers are now examining if a new type of MRI can assess the effectiveness of a chemotherapy regimen for women with breast cancer based on just one round of treatment.

Magnetic Resonance Fingerprinting (MRF) is an innovative MRI method that can examine multiple tissues in the body with a single, time-saving image or "fingerprint." This advanced technology has the potential for a wide range of clinical uses, including early disease identification and gauging how well a treatment is working. Researchers at Case Western Reserve University (Cleveland, OH, USA) are studying whether MRF can provide an early indication of how well neoadjuvant chemotherapy is working in breast cancer patients.

If MRF can deliver consistent insights into the effectiveness of neoadjuvant chemotherapy in breast cancer patients, it could help patients avoid treatments that are not required and enable physicians to explore other options more quickly. Early findings from their research suggest that MRF can accurately evaluate the effectiveness of therapy between seven and ten days after the first cycle of chemotherapy. This could greatly enhance patient care, offering the chance for more individualized treatment plans for many women.

“This study has great potential to bring real survival and quality-of-life benefits to our breast cancer patients,” said Yong Chen, an assistant professor of radiology at the Case Western Reserve School of Medicine. “The ultimate goal is to eliminate ineffective treatments in eligible subjects and instead tailor the treatment methods for optimum therapeutic outcomes for women with breast cancer.”

Related Links:
Case Western Reserve University 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Full Field Digital Mammography Phantom
Mammo FFDM Phantom
New
Color Doppler Ultrasound System
DCU50
New
Ultrasound System
ARIETTA 750SE

Print article
Radcal

Channels

Ultrasound

view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.